Epsilon Healthcare Limited announced that the Company has executed a binding term sheet and manufacturing agreement with privately owned Cannim Australia Pty Ltd. (Cannim). Additionally, the Company has packaged and released for supply the first batch of Cannim's `HummingBud' dried flower products. As a global cannabis company primarily cultivating in Jamaica on a 500-acre farm under Good Agricultural and Collection Practice (GACP), Cannim have significant supply agreements for flower and oils into Germany, the United Kingdom and Australia. Under the manufacturing agreement, Epsilon's world class EU GMP compliant Southport Facility will produce medicinal cannabis products from Cannim raw material at scale for supply into the Australian market as well as for global export. Cannim will pay Epsilon for these manufacturing services on a per-order basis. Over the next two years Epsilon's manufacturing arm, THC Pharma, will receive bulk imports of dried flower for the packaging and release of Australian GMP dried flower. This agreement is terminable at any time by either party. THC Pharma will also work on contract manufacturing opportunities for global third parties using Cannim's cannabis material as an API, including supplying to parties referred to the Company by Cannim.